Aurinia Pharmaceuticals acquiring Kezar Life Sciences

Aurinia Pharmaceuticals acquiring Kezar Life Sciences
Aurinia Pharmaceuticals gains as two board members resign amid holder vote
#earnings before the open tomorrow https://t.co/lObOE0dgsr $MRNA $RCL $DDOG $BUD $PTON $W $NVO $COP $PARA $SHEL $PLNT $K $RACE $REGN $PENN $CG $CAH $H $ATI $AUYTL $LNTH $PZZA $ARGX $ZTS $DINO $SHAK $AUPH $BHC $STWD $TGLS $BWA $PCG $SWK $FOUR $AG $PRVA $AEP $NFE $EQNR $PH $CMRX… https://t.co/ZdNHGu9zTe
Aurinia Pharmaceuticals gains amid renewed takeover speculation
Aurinia Pharmaceuticals gains amid M&A speculation following patent settlement
Aurinia Pharmaceuticals gains on speculation of Otsuka bid
1.92BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
CA05156V1022
CUSIP
05156V102
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
7.03
PEG Ratio
-
Book Value
4.34
Dividend Share
-
Dividend Yield
-
Earnings Share
2.16
Wall Street Target Price
17.00
EPS Estimate Current Year
0.95
EPS Estimate Next Year
1.11
EPS Estimate Current Quarter
0.1975
EPS Estimate Next Quarter
0.2033
Most Recent Quarter
-
Revenue TTM
298,295,008
Gross Profit TTM
233,467,008
EBITDA
153,712,000
Profit Margin
99.97%
Return On Assets TTM
13.66%
Return On Equity TTM
64.98%
Revenue Per Share TTM
2.247
Qtly Revenue Growth YOY
24.40%
Diluted Eps TTM
2.16
Qtly Earnings Growth YOY
56.30%
Trailing PE
7.03
Forward PE
17
Price Sales TTM
6.5444
Price Book MRQ
3.3893
Enterprise Value Revenue
5
Enterprise Value EBITDA
10
760.00
3.03%22.75
2.52%865.00
0.00%88.94
0.00%124.85
-12.62%259.59
-12.18%853.82
-2.26%187.48
-2.14%476.99
-0.98%204.11
-0.83%